Citius Pharmaceuticals (CTXR) Stock Statistics & Valuation Metrics

Citius Pharmaceuticals has a market cap or net worth of $22.46M. The enterprise value is $15.80M.

Citius Pharmaceuticals has 17,012,192 shares outstanding. The number of shares has decreased by -2.65% in one year.

Citius Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -52.56%.

The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -39.43M in profits. Earnings per share was -5.97.

In the last 12 months, operating cash flow was -23.55M and capital expenditures -4.00, giving a free cash flow of -23.55M billion.

Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Citius Pharmaceuticals upcoming earnings date is Feb 6, 2026, Before Open (Confirmed).

Citius Pharmaceuticals as a current ratio of 0.40, with Debt / Equity ratio of 1.36%

In the past 12 months, Citius Pharmaceuticals has paid 576.00K in taxes.

Citius Pharmaceuticals EV to EBITDA ratio is -3.68, with an EV/FCF ratio of -5.04.

Citius Pharmaceuticals has $26.41K in cash and marketable securities with $931.79K in debt, giving a net cash position of $905.38K billion.

Gross margin is -71.09%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Citius Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy